Avidity Biosciences (Avidity Biosciences) Cash And Cash Equivalents : $471.40 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Avidity Biosciences Cash And Cash Equivalents?

Avidity Biosciences's quarterly cash and cash equivalents increased from Sep. 2023 ($85.65 Mil) to Dec. 2023 ($185.08 Mil) and increased from Dec. 2023 ($185.08 Mil) to Mar. 2024 ($471.40 Mil).

Avidity Biosciences's annual cash and cash equivalents increased from Dec. 2021 ($320.45 Mil) to Dec. 2022 ($340.40 Mil) but then declined from Dec. 2022 ($340.40 Mil) to Dec. 2023 ($185.08 Mil).

Avidity Biosciences Cash And Cash Equivalents Historical Data

The historical data trend for Avidity Biosciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avidity Biosciences Cash And Cash Equivalents Chart

Avidity Biosciences Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

94.58

321.46

320.45

340.40

185.08

Avidity Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															118.71	153.88	85.65	185.08	471.40

Avidity Biosciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Avidity Biosciences (NAS:RNA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Avidity Biosciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Avidity Biosciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Avidity Biosciences (Avidity Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avidity Biosciences Inc (NAS:RNA) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121

Website

https://www.aviditybiosciences.com

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Executives

Michael F Maclean	officer: Chief Financial Officer	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
W. Michael Flanagan	officer: Chief Technical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Teresa Mccarthy	officer: Chief Human Resources Officer	10975 N TORREY PINES RD #150, LA JOLLA CA 92037
Arthur A Levin	officer: Chief Scientific Officer	1896 RUTHERFORD ROAD, CARLSBAD CA 92008
Sarah Boyce	director, officer: President and CEO	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eric Mosbrooker	director	C/O HORIZON PHARMA, PLC, ADELAIDE CHAMBERS, PETER STREET, DUBLIN 8 L2 000000
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Jean Jinsun Kim	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Tamar Thompson	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Jae B. Kim	officer: Chief Medical Officer	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Noreen Henig	director	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lilly Eli & Co	10 percent owner	LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Todd C Brady	director	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Michael B. Martin	director	C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037